Cómo citar
Resumen
La osteoporosis es una enfermedad caracterizada por un aumento en el recambio óseo y disminución de la masa ósea asociada a fragilidad esquelética, lo que aumenta el riesgo de caídas y fracturas. Inherente a su presentación, la osteoporosis es asintomática hasta que ocurren las fracturas. Actualmente existe una variedad de medicamentos que pueden ser utilizados en la osteoporosis por lo que es importante conocer cada uno de ellos e individualizar cada paciente para saber cuándo y a quiénes brindar terapia farmacológica. Los más utilizados son los inhibidores de la resorción ósea, los agentes anabólicos, la calcitonina, los moduladores selectivos del receptor de estrógeno y el Denosumab. El desafío en cuanto a esta patología es lograr captar mujeres con alto riesgo para así establecer una terapia de forma temprana con el objetivo de prevenir fracturas.
Palabras clave
Citas
Zhu Y, Huang Z, Wang Y, Xu W. The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review. Journal of Orthopaedic Translation. 2020;22:7-9. Available from: https://doi.org/10.1016/j.jot.2019.08.004
Rossi L, Copes R, Dal Osto L, Flores C, Comim F, Premaor M. Factors related with osteoporosis treatment in postmenopausal women. Medicine. 2018;97(28):1-2. Available from: http://dx.doi.org/10.1097/MD.0000000000011524
Anda S, Evija N, Andris A, Una S, Aivars L. Gray values of the cervical vertebrae detected by cone-beam computed tomography for the identification of osteoporosis and osteopenia in postmenopausal women. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;:4-8. Available from: https://doi.org/10.1016/j.oooo.2021.06.014
Shanks G, Sharma D, Mishra V. Prevention and treatment of osteoporosis in women. OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE. 2019;29(7):202-204. Available from: https://doi.org/10.1016/j.ogrm.2019.04.001
Rizzoli R. Postmenopausal osteoporosis: Assessment and management. Best Practice & Research Clinical Endocrinology & Metabolism. 2018;32(5):740-741. Available from: https://doi.org/10.1016/j.beem.2018.09.005
Rizzoli, R., Biver, E., Bonjour, JP. et al. Benefits and safety of dietary protein for bone health—an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporosis International. 2018;29:1933–1948 Available from: https://doi.org/10.1007/s00198-018-4534-5
Bijelic R, Milicevic S, Balaban J. Risk Factors for Osteoporosis in Postmenopausal Women. Med Arch. 2017;71(1):26-27. Available from: https://doi.org/10.5455/medarh.2017.71.25-28
Briot K, Roux C, Thomas T. 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine. 2018;85(5):521-525. Available from: https://doi.org/10.1016/j.jbspin.2018.02.009
Compston J, Leslie W, McClung M. Osteoporosis. Lancet. 2019;393:364-369.
French K, Emanuele D. Osteoporosis: Increasing Screening and Treatment for Postmenopausal Women. The Journal for Nurse Practitioners. 2019;15(5):349. Available from: https://doi.org/10.1016/j.nurpra.2019.02.014
Compston J, Cooper A, Cooper C. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):42-44. Available from: https://doi.org/10.1007/s11657-017-0324-5
Kanis J, Cooper C, Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30:4-6, 13-15. Available from: https://doi.org/10.1007/s00198-018-4704-5
Arceo-Mendoza R, Camacho P. Postmenopausal Osteoporosis: Latest Guidelines. Endocrinol Metab Clin N Am. 2021;50:167-176. Available from: https://doi.org/10.1016/j.ecl.2021.03.009
Camacho P, Petak S, Binkley N. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE. ENDOCRINE PRACTICE. 2020;26(1):5-11. Available from: https://doi.org/10.4158/GL-2020-0524SUPPL
Anastasilakis A, Evangelatos G, Makras P, Iliopoulos A. Rebound-associated vertebral fractures may occur in sequential time points T following denosumab discontinuation: need for prompt treatment re- initiation. Bone Reports. 2020;12:3. Available from: https://doi.org/10.1016/j.bonr.2020.100267
Shoback D, Rosen C, Black D, Cheung A. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. CLINICAL PRACTICE GUIDELINE UPDATE. 2020;105(3):2-3. Available from: https://doi.org/10.1210/clinem/dgaa048
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2021 Array